cnp-103
Biologicsexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 12, 2025 (NCT06783309)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Zinc transporter 10Immunity, desensitized
Zinc transporter 10 (SLC30A10) immunity, desensitized
- Glucose-6-phosphatase 2Immunity, desensitized
Glucose-6-phosphatase 2 (G6PC2) immunity, desensitized
- Glutamate decarboxylase 2Immunity, desensitized
GAD2 immunity, desensitized
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06783309 | Phase 1/Phase 2 (Phase 2) | May 12, 2025 | Cour Pharmaceutical Development Company, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cour Pharmaceutical Development Company, Inc. | For profit | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1